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Table 2. Strengths and limitations comparison between the 
described vaccines and the old BCG [6, 7].
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Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb) that ranks as the second leading cause of death from an infectious disease worldwide. Efforts to develop new diagnostics, 
drugs and vaccines have intensified during the past decade. A bibliographic analysis of the current status in research and development aiming to briefly describe, evaluate and compare four novel vaccine candidates is 
attempted in this review.
Analysis of four of the state-of-the-art candidate vaccines 
Stop TB Partnership targets [1, 5]:!
• By 2015: Reduce prevalence and death rates by 
50%!
• By 2050: Reduce the global incidence of active 
TB cases to <1 case per 1M population per year 
(=eradication)!
Development of new diagnostics, drugs and vaccines are 
urgently needed as well as better biomarker correlates of 
immunity.
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Table 1. Comparative evaluation of VPM1002, H1, H56, and RUTI® as candidate vaccines in current clinical development [6, 7].!
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Discussion
Boosting vaccines seek 
to extend prime protection by 
subsequent boosting 
vaccination(s).
Immunotherapeutic 
vaccines aspire to shorten 
treatment by synergizing with 
chemotherapy if there is 
active TB or LTBI.
Future vaccines are 
based in 3 different 
approaches: (1)Prime, (2)Boost, 
and (3)Immunotherapy.
Priming 
vaccines aim to replace 
the actual BCG, by either 
attenuation or by 
complementing it with 
new Ags.
Ideal vaccine
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Product name Strengths Limitations
BCG
Protection against miliary !
TB and meningeal TB;!
Cheaply produced
Not effective against pulmonary TB and!
most forms of extrapulmonary TB;!
Durability protection unclear;!
Cannot be boosted with !
repeated vaccination;!
Contraindicated for use in!
immunocompromised individuals;!
Can cause BCGitis (local infection)!
and BCGosis (systemic disease)
VPM1002
Superior protection than !
BCG (even against high !
virulence isolates);!
Induction of CD8+ T cell !
response;!
Activation of Th17 cells !
subset;!
Humoral response
Hly inclusion toxin gene may!
cause additional regulatory scrutiny!
for safety;!
Hygromycin resistance marker !
included in the construct
H1/IC31
Superior protection !
than BCG;!
Long lasting CD4+ !
Th1 response (>2.5 years)
No humoral response triggered;!
Local vaccine-related reactions !
in high dose adjuvanted vaccine;!
Presumptive interference with!
QuantiFERON
H56/IC31
Superior protection than !
BCG and H1;!
Improved prevention of reactivation !
and improved long-term !
containment of LTBI;!
Strong multifunctional CD4+ !
T cell response;!
Effective vaccination !
also after exposure
No detectable CD8+ T cells response;!
No humoral response triggered
RUTI
Induction of CD8+ T cell !
response;!
Humoral response;!
Could also be used as a booster !
and soon after recent infections
Does not decrease bacterial load directly;!
As potent as BCG;!
Dose dependent local adverse !
reactions (mild)
Name Type Route of!administration Strategy Immune response triggered Target population Safety profile Development stage Sponsors
VPM1002
Live recombinant!
BCG (rBCG) !
with an!
endosome escape!
mechanism !
through!
lysteriolysin !
expression and urease !
C deletion
Intradermal injection
Prime!
(Pre-exposure);!
BCG replacement
Stimulation of antigen-specific!
CD4 and improved CD8 T !
cell responses;!
Th17 cells activation;!
Humoral response induction;!
Polyantigenic
__
No safety concerns;!
safe and well!
tolerated (Absence of!
severe adverse effects)
Phase I completed;!
ongoing Phase IIa
Vakzine Projekt!
Management!
(VPM),!
Tuberculosis!
Vaccine Initative!
(TBVI),!
Max Planck!
Institute,!
Statens Serum!
Institute (SSI)!
H1/ IC31
Protein-adjuvant!
fusion of!
Ag85B-ESAT-6 in!
IC31
Intramuscular!
injection (deltoid!
muscle / arm)
Prime-boost!
(Pre-exposure)!
Stimulation of strong and!
long-lasting  Th1 cellular!
response;!
Pauciantigenic;!
No humoral response!
stimulation
Adolescents;!
adults
No safety concerns;!
local adverse events in!
high dose adjuvanted!
vaccine
Phase I completed;!
ongoing Phase IIa
Statens Serum!
Institute (SSI),!
Tuberculosis!
Vaccine Initiative!
(TBVI),!
European and!
Developing Countries!
Clinical Trial!
Partnership (EDCTP),!
Intercell
H56/ IC31
Protein-adjuvant fusion!
of!
Ag85B-ESAT-6-Rv2660c!
in IC31
Intramuscular!
injection
Prime-boost;!
Immunotherapy!
(pre- and post-exposure)!
Stimulation of strong!
multifunctional CD4 T cell!
responses;!
Limitation of reactivation of!
LTBI;!
Pauciantigenic
Adolescents;!
adults __
Phase I completed;!
ongoing Phase I/IIa!
Statens Serum!
Institute (SSI),!
Aeras,!
Intercell!
RUTI
Non-live detoxified!
M. tuberculosis in!
liposomes
Subcutaneous
Immunotherapy*;!
Boost (post- and!
pre-exposure)!!
*Adjunct to LTBI!
INH prophylaxis!
Mixed Th1, Th2, Th3!
response towards latency!
antigens;!
Humoral response induction;!
Polyantigenic!
HIV+;!
adults;!
LTBI diagnosed
No hypersensitivity!
observed
Phase I completed;!
ongoing Phase IIa Archivel Farma, S.L.
Figure 1. Global estimated TB incidence rates, 2012. Source taken from Stop TB 
Partnership[1].!
• 1/3 of the world’s population are infected.!
• Leading killer of people with HIV.!
• Treatment:!
• Too long!
• Ineffective against resistant strains (MDR, XDR, 
TDR)!
• Difficult early diagnosis.!
• Inconsistence efficacy of the only vaccine available, 
BCG (see discussion) [1, 2, 3, 4].
Where are we? In 2012:!8.6M new cases!
1.3M deaths
Where do we need to go?
